Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Authors:
Rosalyn A. Juergens From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Search for other papers by Rosalyn A. Juergens in
Current site
Google Scholar
PubMed Close
 MD
and
Julie R. Brahmer From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Search for other papers by Julie R. Brahmer in
Current site
Google Scholar
PubMed Close
 MD, MSc
Volume/Issue:
Volume 4: Issue 6
Online Publication Date:
Jul 2006
DOI:
https://doi.org/10.6004/jnccn.2006.0049
Full access

Lung cancer is the most common cancer worldwide, accounting for 1.2 million new cases annually. Despite aggressive local management of patients diagnosed with early-stage disease (stages I–IIIA), more than half of patients who have undergone surgical resection will die from complications caused by recurrent lung cancer. Over the past 5 years, results from several large trials assessing the use of adjuvant platinum-based chemotherapy in non-small cell lung cancer have become available. This article reviews the data from the most prominent of these trials and focuses on how the combination of cisplatin and etoposide has been evaluated for use in the adjuvant setting. Cisplatin-based therapy has now been shown to provide a significant survival benefit in several trials and recent meta-analyses. These data have changed the paradigm for how early-stage lung cancer is managed.

Correspondence: Rosalyn A. Juergens, MD, Thoracic Oncology Clinical Fellow, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 401 North Broadway, Johns Hopkins, Baltimore, MD 21205. E-mail: rjuergens@jhmi.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Jemal A, Murray T, Ward E et al.. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.

  • 2.

    American Cancer Society. Estimated new cancer cases and deaths by sex for all sites, US, 2006. Available at: www.cancer.org. Accessed February 14, 2006.

  • 3.

    Schiller JH, Harrington D, Belani CP et al.. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.

  • 4.

    Sandler AB, Gray R, Brahmer J et al.. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial—E4599 (abstract). J Clin Oncol 2005;23(16 suppl):LBA4.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Immerman SC, Vanecko RM, Fry WA et al.. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981;32:23–27.

  • 6.

    Arriagada R, Bergman B, Dunant A et al.. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351–360.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Douillard JY, Rosell R, Delena M et al.. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association (abstract). J Clin Oncol 2005;23(16 suppl):7013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Scagliotti GV, Fossati R, Torri V et al.. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453–1461.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Strauss G, Herndon J, Maddaus M et al.. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALBG) Protocol 9633. J Clin Oncol 2004;22(14 suppl):7019.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Winton T, Livingston R, Johnson D et al.. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2589–2597.

  • 11.

    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899–909.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Postoperative radiotherapy in non-small-cell lung cancer: systemic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257–263.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Kato H, Ichinose Y, Ohta M et al.. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713–1721.

  • 14.

    Hamada C, Ohta M, Wada H et al.. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 2004;22:7002.

  • 15.

    Hotta K, Matsuo K, Ueoka H et al.. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860–3867.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Bria E, Gralla RJ, Raftopoulos H et al.. Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit (abstract). J Clin Oncol 2005;23(16 suppl):7140.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Sedrakyan A, Van Der MJ, O'Byrne K et al.. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004;128:414–419.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Gandara DR, Chansky K, Albain KS et al.. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004–2010.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Keller SM, Adak S, Wagner H et al.. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217–1222.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Mineo TC, Ambrogi V, Corsaro V, Roselli M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 2001;20:378–384.

Copyright:
Copyright © 2006 by the National Comprehensive Cancer Network
Page Numbers:
6
Article Category:
Research Article
Received:
27 Feb 2006
Accepted:
20 Apr 2006
Print Publication Date:
01 Jul 2006
Online Publication Date:
Jul 2006
Keywords:
Adjuvant; chemotherapy; lung cancer; etoposide; platinum

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1967 1203 60
PDF Downloads 508 116 1
EPUB Downloads 0 0 0